tirzepatide in adolescents Journal Club Tirzepatide as a Potential Disease-Modifying

Sample size calculations were based on phase 2 trial data, which predicted a treatment difference of 1.0 in the Female Sexual Function Index-desire domain (FSFI-D) score and about 20.43 points in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13, with a total of 450 evaluable patients providing sufficient statistical power to detect significant differences

"These data are reassuring, but more studies are required to prove causation," lead study author Lucas Mavromatis, a medical student at the NYU Grossman School of Medicine in New York, said in a statement

IFN, interferon

Eli Lillys clinical guidance confirms this explicitly

work: rest ratio 1:1 ratio, 1 min